Emerging research suggest Retatrutide , a dual activator targeting both GLP-1 and another hormone, could provide a significant development for obesity loss . Initial human trials have indicated considerable losses in visceral fat , conceivably exceeding other weight-loss medications . Nevertheless , further study is necessary to fully determine its